Greenwich Lifesciences Inc (GLSI)

$23.67 -0.62 (-2.55%)
Market Cap 356.53M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 271,900
Avg Vol 144,698
Day's Range N/A - N/A
Shares Out 14.68M
Stochastic %K 21%
Beta 1.40
Analysts Strong Sell
Price Target $47.50

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy...

Industry: Biotechnology
Sector: Healthcare
Phone: 832 819 3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
TheinvestmetABCD
TheinvestmetABCD Jun. 5 at 6:13 AM
$GLSI in my opinion the decline from $29 to $22 was due to ATM usage. The company needs to sell shares when we have some good news and volume to bridge the time until a partnership or interim analysis where price will rerate a lot to place a bigger offering. When watching Snehal´s latest interview, I can understand why the price got even more under pressure. The market does not like uncertainity especially in a high risk biotech stock. The main problem is that the interim analysis will be changed and the market does not know what to expect (even if what I believe the change will be positive and in our favour). How many recurrences are needed now instead of 14? How long will it take to reach the new goal for interim analysis? How will the company finance the time gap? What if EMA does not approve the change like the FDA did?
1 · Reply
twegs
twegs Jun. 5 at 2:55 AM
$GLSI One thing to add, from the 10Q: quarterly expenses increased this last quarter to about 5.6 million. if that remains constant, they will need to hit the ATM alot more this year with only 10.5 million in cash. So, at a fair estimate of 22$ a share, (just a guess), they will need to sell about 275,000 more shares to cover the rest of the year.
1 · Reply
Rolltide2020
Rolltide2020 Jun. 5 at 2:19 AM
$GLSI What a strange time for your first post!! You would have anyone believe that you have been a silent supporter for all this time, but now you just had to speak up? I have never blocked anyone, but you may become the first.
0 · Reply
msgbrdinfo
msgbrdinfo Jun. 5 at 12:28 AM
$GLSI The sooner Glsi makes a deal with big pharma, the better. People are dumb who think a development partnership would mean less money for glsi. It just means they get up front money now (the share price goes to 3 digits) and they get the big money after fda approval and fill buyout. The sooner ,the better. 💯
2 · Reply
Toontje1
Toontje1 Jun. 5 at 12:02 AM
$GLSI Does it matter if they dilute till 15 million shares. They will have 30 million extra if they do that. Must be enough. Don’t cry about dilution. I do think we all know burn rate is waaaay lower than an average bio fase 3 trail.
0 · Reply
profitraider
profitraider Jun. 4 at 11:05 PM
$GLSI Boyz… will this one be able to survive?
1 · Reply
Stock_profit_03
Stock_profit_03 Jun. 4 at 10:04 PM
$GLSI added 1k shares today
0 · Reply
skiddy5
skiddy5 Jun. 4 at 9:19 PM
$GLSI initial 14 event threshold timeline now longer. Current treatments more effective than initially projected. Introduces smaller potential market argument. Discussing smaller number of events with FDA so a bit of catalyst there but how they do all this with only 10MM especially if they need another 18+ months beyond me. Narrative changed a tad.
4 · Reply
EJBBBBB
EJBBBBB Jun. 4 at 9:03 PM
$GLSI bought at 10 might be out something is up had a huge loss an a stock very similar to this did not end well was hopi g this would be a huge win now om doubting it
2 · Reply
Rolltide2020
Rolltide2020 Jun. 4 at 7:54 PM
$GLSI I have a significant amount of money here. I fully understand that any morning I could wake up one day to see 100% of it gone. It would suck, but I would be ok. If I ever woke up to see 500% or 1000% of it gone, I would have to have to take a short walk off a tall building. Given the $5 to $10 billion potential for GLSI, and the fact that life changing news could have at any time (not predicting a specific date, but someday), why would anyone risk such an oversized loss for a maximum double-up (minus all the borrowing cost incurred along the way)? But that's just me.
2 · Reply
Latest News on GLSI
Greenwich LifeSciences presents FLAMINGO-01 data at ASCO

2026-06-01T14:32:25.000Z - 3 days ago

Greenwich LifeSciences presents FLAMINGO-01 data at ASCO

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Jun 1, 2026, 8:15 AM EDT - 3 days ago

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Greenwich LifeSciences provides update on 10-K filing

2026-06-01T10:21:46.000Z - 3 days ago

Greenwich LifeSciences provides update on 10-K filing

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Jun 1, 2026, 6:00 AM EDT - 3 days ago

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

May 22, 2026, 4:30 PM EDT - 13 days ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Greenwich LifeSciences says Form 10-K ‘still being audited’

2026-04-30T10:11:17.000Z - 5 weeks ago

Greenwich LifeSciences says Form 10-K ‘still being audited’

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Apr 23, 2026, 6:00 AM EDT - 6 weeks ago

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences receives noncompliance notification from Nasdaq

2026-04-22T21:05:16.000Z - 6 weeks ago

Greenwich LifeSciences receives noncompliance notification from Nasdaq

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 22, 2026, 5:00 PM EDT - 6 weeks ago

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026

2026-04-20T10:17:19.000Z - 6 weeks ago

Greenwich LifeSciences presents Flamingo-01 Phase 3 results from AACR 2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Apr 20, 2026, 6:00 AM EDT - 6 weeks ago

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences reports cash balance of $10.5M as of March 31

2026-04-14T10:21:37.000Z - 7 weeks ago

Greenwich LifeSciences reports cash balance of $10.5M as of March 31

Greenwich LifeSciences Provides Update on Financing Strategy

Apr 14, 2026, 6:00 AM EDT - 7 weeks ago

Greenwich LifeSciences Provides Update on Financing Strategy

Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01

2026-04-07T10:06:43.000Z - 2 months ago

Greenwich LifeSciences updates on new patent claims based on FLAMINGO-01

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Apr 7, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial

2026-03-19T10:12:27.000Z - 2 months ago

Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Mar 19, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences provides update on presentations at AACR Meeting 2026

2026-03-18T10:11:20.000Z - 2 months ago

Greenwich LifeSciences provides update on presentations at AACR Meeting 2026

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Mar 18, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial

2026-03-17T10:21:32.000Z - 2 months ago

Greenwich LifeSciences’ GLSI-100 reduces recurrence rate in Phase 3 trial

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Mar 17, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01

2026-03-16T10:32:26.000Z - 2 months ago

Greenwich announces use of commercially manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Mar 16, 2026, 6:00 AM EDT - 2 months ago

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial

2026-03-03T11:05:58.000Z - 3 months ago

Greenwich LifeSciences provides update on screen rate in FLAMINGO-01 trial

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Mar 3, 2026, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Feb 24, 2026, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial

2026-01-27T11:11:03.000Z - 4 months ago

Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trial

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Jan 27, 2026, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA

2026-01-22T11:21:40.000Z - 4 months ago

Greenwich LifeSciences’ GP2 breast cancer therapy approved by FDA

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Jan 22, 2026, 6:00 AM EST - 4 months ago

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright

2025-12-30T11:10:33.000Z - 5 months ago

Greenwich LifeSciences price target raised to $50 from $39 at H.C. Wainwright

Greenwich LifeSciences extends lock-up of directors, officers to September 30

2025-12-29T11:15:15.000Z - 5 months ago

Greenwich LifeSciences extends lock-up of directors, officers to September 30

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Dec 29, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters

2025-12-22T11:21:11.000Z - 5 months ago

Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Dec 22, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm

2025-12-15T11:16:50.000Z - 6 months ago

Greenwich announces 80% recurrence rate reduction in FLAMINGO-01 arm

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Dec 15, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial

2025-12-08T11:10:12.000Z - 6 months ago

Greenwich LifeSciences: Enrollment complete in open label arm oFLAMINGO-01 trial

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Dec 8, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Dec 3, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 9, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 8 months ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 9 months ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 10 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 10 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 10 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 10 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 1 year ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 2 years ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

TheinvestmetABCD
TheinvestmetABCD Jun. 5 at 6:13 AM
$GLSI in my opinion the decline from $29 to $22 was due to ATM usage. The company needs to sell shares when we have some good news and volume to bridge the time until a partnership or interim analysis where price will rerate a lot to place a bigger offering. When watching Snehal´s latest interview, I can understand why the price got even more under pressure. The market does not like uncertainity especially in a high risk biotech stock. The main problem is that the interim analysis will be changed and the market does not know what to expect (even if what I believe the change will be positive and in our favour). How many recurrences are needed now instead of 14? How long will it take to reach the new goal for interim analysis? How will the company finance the time gap? What if EMA does not approve the change like the FDA did?
1 · Reply
twegs
twegs Jun. 5 at 2:55 AM
$GLSI One thing to add, from the 10Q: quarterly expenses increased this last quarter to about 5.6 million. if that remains constant, they will need to hit the ATM alot more this year with only 10.5 million in cash. So, at a fair estimate of 22$ a share, (just a guess), they will need to sell about 275,000 more shares to cover the rest of the year.
1 · Reply
Rolltide2020
Rolltide2020 Jun. 5 at 2:19 AM
$GLSI What a strange time for your first post!! You would have anyone believe that you have been a silent supporter for all this time, but now you just had to speak up? I have never blocked anyone, but you may become the first.
0 · Reply
msgbrdinfo
msgbrdinfo Jun. 5 at 12:28 AM
$GLSI The sooner Glsi makes a deal with big pharma, the better. People are dumb who think a development partnership would mean less money for glsi. It just means they get up front money now (the share price goes to 3 digits) and they get the big money after fda approval and fill buyout. The sooner ,the better. 💯
2 · Reply
Toontje1
Toontje1 Jun. 5 at 12:02 AM
$GLSI Does it matter if they dilute till 15 million shares. They will have 30 million extra if they do that. Must be enough. Don’t cry about dilution. I do think we all know burn rate is waaaay lower than an average bio fase 3 trail.
0 · Reply
profitraider
profitraider Jun. 4 at 11:05 PM
$GLSI Boyz… will this one be able to survive?
1 · Reply
Stock_profit_03
Stock_profit_03 Jun. 4 at 10:04 PM
$GLSI added 1k shares today
0 · Reply
skiddy5
skiddy5 Jun. 4 at 9:19 PM
$GLSI initial 14 event threshold timeline now longer. Current treatments more effective than initially projected. Introduces smaller potential market argument. Discussing smaller number of events with FDA so a bit of catalyst there but how they do all this with only 10MM especially if they need another 18+ months beyond me. Narrative changed a tad.
4 · Reply
EJBBBBB
EJBBBBB Jun. 4 at 9:03 PM
$GLSI bought at 10 might be out something is up had a huge loss an a stock very similar to this did not end well was hopi g this would be a huge win now om doubting it
2 · Reply
Rolltide2020
Rolltide2020 Jun. 4 at 7:54 PM
$GLSI I have a significant amount of money here. I fully understand that any morning I could wake up one day to see 100% of it gone. It would suck, but I would be ok. If I ever woke up to see 500% or 1000% of it gone, I would have to have to take a short walk off a tall building. Given the $5 to $10 billion potential for GLSI, and the fact that life changing news could have at any time (not predicting a specific date, but someday), why would anyone risk such an oversized loss for a maximum double-up (minus all the borrowing cost incurred along the way)? But that's just me.
2 · Reply
mshah1615
mshah1615 Jun. 4 at 7:18 PM
$GLSI let’s see how this stock at the end of day
0 · Reply
insidersruleloosersdrool
insidersruleloosersdrool Jun. 4 at 6:51 PM
$GLSI This has been a disappointment overall. I thought once the Financials were cleaned up we would see a little respect. Guess not. I own both this and SLS, which has had a bit of turmoil the last three days as well. I hoping both of these little diamonds in the rough polish up nicely someday.
1 · Reply
mshah1615
mshah1615 Jun. 4 at 5:18 PM
$GLSI Today’s Action is very Encouraging i see there is undery Support Volume is very good price is holding up To me some kind of News coming Soon ( (within week)
1 · Reply
yft212
yft212 Jun. 4 at 5:10 PM
$GLSI apparently we need to contact Reader’s Digest and clue them in.
0 · Reply
LIGator
LIGator Jun. 4 at 5:07 PM
$GLSI I wouldn’t want to pay 10% per year to finance anything, the shorts are paying 10% per MONTH. I will take every penny that I get from the FPL payment tomorrow and buy more shares.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jun. 4 at 4:59 PM
$GLSI I picked up another 300 shares at $23.20
0 · Reply
ATXAMPEREStrategies
ATXAMPEREStrategies Jun. 4 at 4:48 PM
$GLSI volume looks good.
0 · Reply
TXcountry
TXcountry Jun. 4 at 4:25 PM
$GLSI correction 48k
1 · Reply
TXcountry
TXcountry Jun. 4 at 4:19 PM
$GLSI someone just bought 25k shares
0 · Reply
telomerase
telomerase Jun. 4 at 4:12 PM
$GLSI sorry guys I bought back in so it has to drop for a while now 🤪
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jun. 4 at 4:00 PM
$GLSI accumulation zone
0 · Reply
Kamal2020
Kamal2020 Jun. 4 at 3:42 PM
$GLSI again testing 22 🤦‍♂️🤦‍♂️
0 · Reply